First Half Results Presentation Fiscal Year 2012

(April 1, 2012 – September 30, 2012)

This English translation contains modified extracts from a results presentation held on November 5, 2012. Forecasts contained in this material are based on information available at the time of presentation, and no commitment or guarantee is given that business policies will be implemented or target figures achieved.

For further information: Corporate Communications Division

HP URL: www.mgc.co.jp





Contents

1. H1 resultsp.5
2. H1 results by segment and H2 outlookp.9
3. Full-year forecastsp.11
4. Structural reform of loss-making businessesp.21
5. Appendixp.23



FY2012 H1 consolidated results

(Billion yen)

	FY2012 H1	FY2011 H1	Change	Change (%)
Net sales	232.7	230.0	2.7	1.2 %
Operating income	3.9	7.5	(3.5)	(47.6 %)
Equity in earnings of affiliates	9.9	10.4	(0.4)	(7.6 %)
Ordinary income	11.2	16.2	(4.9)	(30.7 %)
Net income before tax	7.7	14.0	(6.2)	(44.9 %)
Net income	8.1	12.1	(3.9)	(33.0 %)

Net income per share (yen)	17.97	26.79	(8.82)
Interim dividend (yen)	6.0	6.0	-

- Sales volume of aromatic chemicals and electronic materials declined due to sluggish demand, and market prices declined for methanol and ammonia derivatives; however, the sales volume of electronic chemicals and polycarbonate increased, and the sales price of methanol remained high. Net sales, therefore, increased only slightly.
- Operating income declined ¥3.5 billion, primarily due to narrower margins resulting from declines in the price of chemicals generally and lower sales volumes of polycarbonate sheets and films, and electronic materials.
- Equity in earnings of affiliates achieved prior-year levels due to the results of overseas methanol producing companies; however, ordinary income was lower than the prior-year level due to lowered operating income.
- Net income declined ¥3.9 billion due to an extraordinary loss, including loss on valuation of investment securities.
- ➤ The interim dividend was unchanged at ¥6 per share.

^{*}Subsequent figures in this presentation are rounded down to the nearest unit

FY2012 H1 consolidated non-operating and extraordinary items



	FY2012 H1	FY2011 H1	Change
Non-operating items	7.3	8.7	(1.4)
Equity in earnings of affiliates	9.9	10.4	(0.4)
Financing income (loss)	(0.3)	0.0	(0.3)
Exchange rate loss	(8.0)	(0.5)	(0.3)
Other	(1.3)	(1.1)	(0.2)

(Billion	ven)
DIIIIOI	VGII)

- **Extraordinary income** 0.3 (0.1)0.4 Insurance income, Other 0.1 0.4 (0.3)0.1 0.0 0.1 Other (3.8)(2.6)(1.1)**Extraordinary loss** Loss on devaluation of (1.6)(1.5)(0.0)investment securities Provision for compensation (8.0)(8.0)expenses Expenditure on environmental (8.0)(8.0)improvement measures **Environmental improvement** (0.3)(0.4)0.1 expensive (0.1)(0.1)Loss on litigation (0.0)(0.0)(0.0)Impairment loss Less on disaster (0.5)0.5
- The loss on valuation of investment securities amounted to ¥1.6 billion
- ➤ To provide for the payment of compensation based on the licensing agreement, accrued compensation expenses of ¥0.8 billion
- Estimated loss due to the withdrawal of coenzyme Q10 business, ¥0.8 billion in accrued loss on business liquidation

FY2011 H1 consolidated balance sheets



(Billion yen)

	As of Sep. 30, 2012	As of March 31, 2012	Change	Remarks
Current assets	260.9	254.0	6.9	
Cash	33.4	27.4	5.9	
Trade notes and accounts receivable	124.7	122.0	2.7	
Inventories	83.2	760	7.1	
Other	19.5	28.4	(8.9)	Capex : ¥17.7 bn
Property, plant and equipment	350.7	341.2	9.5	Depreciation and amortization: minus ¥10.7bn
Tangible and intangible assets	201.6	194.4	7.2	
Investment securities	133.2	132.9	0.2	
Other assets	15.8	13.8	2.0	
Total assets	611.7	595.2	16.4	
Liabilities	314.0	301.3	10.8	
Trade notes and accounts payable	82.5	69.4	13.0	
Interest-bearing debt	180.3	185.1	(4.8)	
Other	51.1	48.5	2.6	
Net assets	297.6	292.1	5.5	Shareholders' equity ratio: 2012/9/30: 47.0%
Shareholders' equity	319.9	314.6	5.3	2012/3/31: 47.3%
Other comprehensive income	(32.7)	(32.9)	0.1	
Minority interests	10.4	10.4	0.0	
Total liabilities and net assets	611.7	595.2	16.4	



FY2012 H1 consolidated cash flows

e	(Billion yen)
3	
)	
ļ	
)	
ļ	
<u> </u>	
•	

	FY2012 H1	FY2011 H1	Change
Operating activity cash flows	24.8	23.9	0.8
Net income before tax	7.7	14.0	(6.2)
Depreciation expenses	10.7	13.4	(2.6)
Equity in earnings of affiliates	(9.9)	(10.4)	0.4
Dividends received from equity method affiliates	7.4	7.7	(0.3)
Working capital, etc.	9.6	1.2	8.4
Income taxes paid	(8.0)	(2.0)	1.2
Investing activity cash flows	(15.5)	(20.2)	4.7
Capital expenditure	(14.7)	(19.8)	5.1
Investment and financing, etc.	(0.8)	(0.3)	(0.4)
Financing activity cash flows	(8.2)	(22.7)	14.5
Change in borrowings and bonds	(5.1)	(20.4)	15.2
Dividends paid	(3.1)	(2.3)	(0.7)
Effect of exchange rate changes on cash and cash equivalents	(0.4)	(0.9)	0.5
Increase (decrease) in cash and cash equivalents	0.6	(20.0)	20.6
Cash and cash equivalents at beginning of year	35.7	46.7	(11.0)
Cash and cash equivalents at end of year	36.3	26.7	9.5

FY2011 consolidated full-year forecasts MGC



(Billion yen)

	FY2012 (Nov. forecasts)	FY2012 (Aug. forecasts)	(Aug. Change		Change
Net sales	470.0	480.0	(10.0)	452.2	17.7
Operating income	10.0	13.0	(3.0)	9.0	0.9
Equity in earnings of affiliates	20.0	20.0	0.0	20.5	(0.5)
Ordinary income	26.0	28.0	(2.0)	26.1	(0.1)
Net income before tax	15.0	25.0	(10.0)	25.4	(10.4)
Net income	12.0	23.0	(11.0)	12.3	(0.3)

Net income per share (yen)	26.56	50.90	(24.34)	27.28	(0.72)
Interim dividend (yen)	12.0	12.0	ı	12.0	ı

Reasons for change in Aug. forecasts

- > Operating income is expected to decline ¥3.0 billion, mainly due to deterioration in profitability of a polycarbonate subsidiary in China in H2, and lower sales volume of general-purpose BT materials.
- > Equity in earnings of affiliates will achieve the forecast level announced in August thanks to steady performance by overseas methanol producing companies.
- > Financial loss in structural reform of loss-making businesses is estimated as accurately as possible, and is calculated into the extraordinary loss.
- Net income fell short of Aug. forecasts by ¥11.0 billion, while staying at the same level as the previous year.
- ➤ At ¥12 per share, the annual dividend forecast is the same as the previous year.

FY2012 consolidated forecasts by segment (Rillion ven)

		FY2012 (results/forecasts)			FY	′2011 (resu	Its)	Change		
		H1 (results)	H2 (forecasts)	FY (forecasts)	H1	H2	FY	H1	H2	FY
Net	sales	232.7	237.2	470.0	230.0	222.1	452.2	2.7	15.1	17.7
	Natural Gas Chemicals	81.2	82.7	163.9	77.7	82.2	159.9	3.4	0.5	4.0
	Aromatic Chemicals	65.1	61.6	126.7	68.4	58.7	127.1	(3.2)	2.8	(0.4)
	Specialty Chemicals	65.1	66.8	131.9	60.2	61.8	122.1	4.9	4.9	9.8
	Information & Advanced Materials	26.4	30.5	57.0	28.2	23.6	51.8	(1.7)	6.9	5.1
	Other	0.3	0.8	1.2	0.4	0.5	0.9	(0.0)	0.3	0.3
	Eliminations and Corporate	(5.5)	(5.4)	(10.9)	(4.9)	(4.8)	(9.8)	(0.6)	(0.5)	(1.1)
Ope	rating income	3.9	6.0	10.0	7.5	1.5	9.0	(3.5)	4.4	0.9
	Natural Gas Chemicals	(0.6)	1.1	0.5	0.4	(0.0)	0.3	(1.0)	1.2	0.1
	Aromatic Chemicals	(0.6)	(0.3)	(0.9)	0.7	(1.7)	(1.0)	(1.3)	1.4	0.0
	Specialty Chemicals	4.4	4.2	8.6	3.7	3.7	7.5	0.7	0.4	1.1
	Information & Advanced Materials	2.0	2.1	4.1	3.4	0.3	3.7	(1.3)	1.7	0.3
	Other	0.1	0.2	0.3	0.2	0.0	0.2	(0.0)	1.0	0.0
	Eliminations and Corporate	(1.4)	(1.2)	(2.6)	(1.0)	(0.7)	(1.8)	(0.3)	(0.4)	(8.0)

For reference:

Earnings in equity affiliates	9.9	10.0	20.0	10.4	10.1	20.5	(0.4)	(0.1)	(0.5)

Natural Gas Chemicals



	FY2012	FY2012 (results/forecasts)			2011 (result	:s)	Change			
	H1 (results)	H2 (forecast)	FY (forecast)	H1	H2	FY	H1	H2	FY	
Net sales	81.2	82.7	163.9	77.7	82.2	159.9	3.4	0.5	4.0	
Operating income	(0.6)	1.1	0.5	0.4	(0.0)	0.3	(1.0)	1.2	0.1	

(Billion yen)

FY2012 H1 (results)

> Methanol

Sales volumes were the same level as FY2011 H1. Despite market prices continued higher level (Asia spot average price: \$349→\$385), increasing procurement costs due to rising market price resulted in higher revenue and lower earnings.

> Methanol and ammonia derivatives

Revenue and earnings from ammonia were the same level as FY2011 H1 due to higher market prices. Sales volumes of neopentylglycol and market prices of MMA-based products declined, but resulting in earnings roughly in line with FY2011 H1.

> Enzymes and coenzymes

Coenzyme Q10 sales volumes trended at low levels, but earnings was the same level as FY2011 H1.

➤ Natural gas and other energy

Revenue and Earnings increased as crude oil prices rose.

FY2012 H2 (forecasts)

Sales volumes and prices are expected to remain high and appropriate the settlement of the account for the purchase temporary price of the first half, contributing to an increase in revenue and earnings.

Although ammonia market prices are expected to remain high, sales volumes of neopentylglycol and overseas market prices of MMA-based products continue lower level. Profitability is expected to remain roughly level with H1.


Revenue and earnings of coenzyme Q10 continue lower level, due to withdrawal from the business. (ending production by the end of March)

Revenue and earnings expected the same level with H1.



Natural Gas ChemicalsMethanol prices, equity in earnings

Methanol / Crude oil prices



Equity in earnings

FY2012 H1 (results)

While a slowdown can be seen in the Chinese economy, which was a driver of demand, there are concerns about the supply of Iranian methanol being affected by the strengthening of economic sanctions against the country. Therefore the balance of supply and demand trended without large fluctuations.

Market prices remained high. Earnings of overseas methanol producing companies achieved the same level as Aug. forecasts.

FY2012 H2 (forecasts)

No significant change from the environment of H1. Equity in earnings is expected to be at the same level as Aug. forecasts.

Outlook for FY2012 H2 onward

Strong demand will absorb the expansion of production capacity of the new plant or expansion. Coal-based plants in China are expected to suspend and restart operations in response to fluctuations in the market. Based on this assumption, the Asia spot average price is expected to move within the 350-400\$/MT range.

MGC

Natural Gas Chemicals Capital expenditure, product development

Product	Status
New products	 ♦ SPG-PET ALTESTER®: Polyester resin with improved heat resistance and transparency ⇒ Developing as a packaging application in the field of foods and electronic components ⇒ Constructed 1,800t/y semi-commercial plant in Niigata (completed in September 2012) ♦ Antibody drugs ⇒ Business alliance with Taiwanese antibody drugs development venture (GlycoNex Inc.) ⇒ Beginning operations as an antibody production process contract research organization (CRO) and contract manufacturing organization (CMO) ⇒ Constructing bench scale facility in Niigata laboratory ♦ Pyrroloquinoline quinone (PQQ): Health food ingredient ⇒ Full-fledged marketing underway in U.S. ⇒ Consider future construction of large-scale facility depending on market response

Aromatic Chemicals



	FY2012	(results/for	recasts)	FY	2011 (resul	ts)	Change			
	H1 (results)	H2 (forecasts)	FY (forecasts)	H1	H2	FY	H1	H2	FY	
Net sales	65.1	61.6	126.7	68.4	58.7	127.1	(3.2)	2.8	(0.4)	
Operating income	(0.6)	(0.3)	(0.9)	0.7	(1.7)	(1.0)	(1.3)	1.4	0.0	

(Billion yen)

FY2012 H1 (results)

>Specialty aromatic chemicals

Revenue and earnings declined due to lower sales volumes in Nylon-MXD6 and aromatic aldehydes for overseas markets, and meta-xylenediamine for the domestic market.

➤ Purified isophthalic acid

Despite sales volume being at the same level as the previous period, revenue and earnings declined because sales prices did not proceed due to oversupply of purified isophthalic acid and a downturn in the polyester chain.

FY2012 H2 (forecasts)

Nylon-MXD6 and aromatic aldehydes for overseas markets and meta-xylenediamine for domestic market are expected to increase.

Sales volume is expected to increase; however, the economic environment will not improve significantly. It is also expected that due to the added cost of periodic repairs at the Mizushima plant, severe loss situation will continue.

Aromatic Chemicals



Capital expenditure, product development

Product	Status
Meta- xylenediamine	⇔ Current capacity: Mizushima plant: 25,000 t/y; Niigata plant: 30,000 t/y ⇒ planning to increase Mizushima plant capacity by 5,000 t/y in 2014
	 ♦ Transparent & highly heat resistant polyimide film Neopulim® ⇒ Developing market as a glass substrate substitute in flexible display and LCD panel applications ⇒ Seeking alliances and collaboration with film makers
New products	 ⇒ Hydrogenated poly-carboxylic acid ⇒ Demand increasing for use as raw material monomer in LED sealant and display component applications ⇒ Constructed semi-commercial plant at Mizushima plant (start operations from April 2012)
	 ♦ Highly heat resistant bio-based polyamide LEXTER® ⇒ Raw material is sebacic acid, which is plant-derived (castor oil) ⇒ Trial operations completed for increase in Nylon-MXD6 production at Niigata plant

MGC

Specialty Chemicals

	FY2012	(results/for	recasts)	FY	2011 (resul	ts)	Change			
	H1 (results)	H2 (forecast)	FY (forecast)	H1	H2	FY	H1	H2	FY	
Net sales	65.1	66.8	131.9	60.2	61.8	122.1	4.9	4.9	9.8	
Operating income	4.4	4.2	8.6	3.7	3.7	7.5	0.7	0.4	1.1	

(Billion yen)

FY2012 H1 (results)

> Inorganic chemicals for industrial use

Revenue and earnings increased due to higher sales volumes of hydrogen peroxide compared with the figure for the priorperiod affected by the major natural disaster, although the level of domestic demand was lower.

> Electronic chemicals

Revenue and earnings of super-pure hydrogen peroxide for the overseas market and hybrid chemicals for semiconductors increased. Overseas subsidiaries recorded firm revenue and earnings.

> Engineering plastics

In PC, revenue and earnings increased due to higher sales volume compared with the prior-period, suspended production due to the disaster. POM sales volume was strong; however, earnings decreased due to higher raw material prices.

In PC sheets and films, demand for film for flat panel display

applications decreased, resulting in lower revenue and earnings.

FY2012 H2 (forecasts)

Hydrogen peroxide is expected to decline in sales volume due to weakening domestic demand.

Super-pure hydrogen peroxide for overseas demand remains strong. Revenue and earnings of hybrid chemicals are expected to increase due to higher sales for semiconductors. Overseas subsidiaries are expected to perform favorably overall.

In PC, losses increase due mainly to delay in full operations at the Shanghai subsidiary. In POM, revenue and earnings are expected to be at the same level as H1.

In PC sheets and films, sales of new grade films for FPD are expected to increase.



Specialty Chemicals Capital expenditure, product development

Product	Status
Electronic chemicals	 Construction underway to expand super-pure hydrogen peroxide facilities at overseas subsidiaries (U.S., S. Korea, Taiwan, Singapore) ⇒Total increase in capacity of 95,000t/y (start of commercial operations to begin in phases from 2012 to 2013)
Polycarbonate	♦ China: Shanghai 80,000 t/y; started commercial operations in June 2012 ⇒Developed as location combining materials production, compounds production and technical advice
Polyacetal	 ♦ Expansion of facilities in Thailand to boost capacity by 40,000 t/y (start of commercial operations scheduled for 2013 Q2) ⇒Completed modifications for additional 5,000 t/y ♦ Expansion of facilities in South Korea to boost capacity by 35,000 t/y (start of commercial operations scheduled for 2014 Q1)
Hard-coated sheets	Promoting sales for new grade products for application as substitute material for cover glass in smartphones

Information & Advanced Materials



(Billion yen)

	FY2012	(results/fo	recasts)	FY	2011 (resul	ts)	Change			
	H1 (results)	H2 (forecasts)	FY (forecasts)	H1	H2	FY	H1	H2	FY	
Net sales	26.4	30.5	57.0	28.2	23.6	51.8	(1.7)	6.9	5.1	
Operating income	2.0	2.1	4.1	3.4	0.3	3.7	(1.3)	1.7	0.3	

FY2012 H1 (results)

> Electronic materials

In BT materials, although the sales for high-performance fields were good, the downturn in demand for general-purpose uses continued, resulting in a decrease in revenue and earnings.

Highly efficient products by Japan Circuit Industrial Co., Ltd. met their success, resulting in an increase in both revenue and earnings.

> Oxygen absorbers

Revenue and earnings were at the same level as FY2011 H1 with steady demand in domestic and overseas markets.

FY2012 H2 (forecasts)

In BT materials, although the sales for high-performance fields will be good, the demand environment for generalpurpose uses will not improve, and revenue and earnings will decrease.

Japan Circuit Industrial Co., Ltd. sales of highly efficient products will expand, and both revenue and earnings are expected to increase.

Sales volumes in both Japan and overseas are expected to remain at a high level, resulting in higher revenue and earnings than H1.

Information and Advanced Materials



Capital expenditure, product development

Projects	Status
BT materials	
High performance epoxy materials	 Started outsourcing production to Chinese company, developing Chinese market
	♦ AGELESS® Expanding and marketing micro grade corresponding to individual food packaging ♦ PharmaKeep® Oxygen absorber for medical supplies and instruments. Excellent performance in the maintenance of medicinal properties, marketing for the pharmaceutical companies

MGC Will2014 Restructuring loss-making businesses -1



Progress Status

Coenzyme Q10

- O Decided to withdraw from Coenzyme Q10 business. We could not expect improvement of profit in this business because of continuing oversupply due to the entry of overseas makers and expansion by existing makers.
- O Production will stop by the end of March, 2013.
- O In the first half of FY2012, increased ¥0.8 billion as provision for loss on business liquidation.
- O Further reduction of fixed costs.
- O Aiming to make PQQ (Pyrroloquinoline quinone) a profit earning business at an early stage and the next pillar of the biochemical business domain.

MGC Will2014 Restructuring loss-making businesses -2 MGC



Ammonia

- O Production at the Niigata plant will stop in the near future and MGC will change to procurement from external sources because of high maintenance costs of aging facilities and inefficient production by small lots.
- O Supply of ammonia to its important derivatives will continue. (metaxylenediamine, methylamine, etc.)
- 0 Detailed plans for securing supply sources and maintaining suitable logistics will be formulated.
- O Further reduction of fixed costs.

Isophthalic acid

- 0 Isophthalic acid is a key product to uphold the sales of specialty products business (meta-xylenediamine, Nylon-MXD6, etc.), which is a main focus of MGC's aromatic chemicals division.
- Optimally balanced production scales and costs are being considered O simultaneously for both isophthalic acid and its material, meta-xylene.

MGC

Appendix 1: consolidated ordinary income by segment

(Billion yen)

		FY2012 (results, forecasts)				FY2011 (results)		Change			
		H1 (results)	H2 (forecasts)	FY (forecasts)	H1	H2	FY	H1	H2	FY	
Orc	linary income	11.2	14.7	26.0	16.2	9.9	26.1	(4.9)	4.8	(0.1)	
	Natural Gas Chemicals	6.5	8.0	14.5	8.1	7.0	15.2	(1.5)	0.9	(0.6)	
	Aromatic Chemicals	(1.1)	(1.0)	(2.1)	0.1	(2.3)	(2.1)	(1.3)	1.2	(0.0)	
	Specialty Chemicals	4.5	4.9	9.4	4.4	4.0	8.4	0.1	8.0	0.9	
	Information and Advanced Materials	1.9	2.3	4.2	3.3	0.3	3.7	(1.4)	1.9	0.4	
	Others	0.7	0.9	1.6	0.9	0.6	1.6	(0.1)	0.2	0.0	
	Eliminations and Corporate	(1.4)	(0.3)	(1.7)	(0.9)	0.1	(0.7)	(0.5)	(0.4)	(0.9)	

Appendix 2: Key indicators (1)



1.Key indicators (consolidated)

(100 million yen)

	FY2005	FY2006	FY2007	FY2008	FY2009	FY2010	FY2011	FY2012
	Results	Results	Results	Results	Results	Results	Results	Forecasts
Capital expenditure	175	295	394	351	276	354	424	330
(Of which, H1)	(132)	(147)	(160)	(193)	(141)	(146)	(224)	(177)
Depreciation & amortization (Of which, H1)	188	Note) 198	245	289	295	290	277	230
	(94)	(91)	(110)	(135)	(137)	(138)	(134)	(107)
R&D expenditure	106	115	136	147	162	164	174	153
(Of which, H1)	(55)	(58)	(66)	(67)	(74)	(74)	(88)	(72)
Employees (as of March 31)	4,466	4,561	4,686	4,902	4,920	4,979	5,216	5,345
Earnings per share (Yen)	70.98	86.63	87.01	15.30	12.89	41.92	27.28	26.56
ROA (Return on assets)	9.5%	10.5%	10.2%	1.2%	1.4%	6.5%	4.5%	4.2%
ROE (Return on equity)	14.5%	15.0%	13.7%	2.5%	2.2%	6.9%	4.4%	4.2%
Dividend (yen)	10.0	14.0	16.0	16.0	8.0	8.0	12.0	12.0
(Of which, interim dividend)	(4.0)	(6.0)	(8.0)	(8.0)	(4.0)	(4.0)	(6.0)	(6.0)

2. Capex, depreciation and amortization by segment (consolidated)

(100 million yen)

		FY2005 Results	FY2006 Results	FY2007 Results	FY2008 Results	FY2009 Results	FY2010 Results	FY2011 Results
	Natural Gas Chemicals	26	62	56	107	71	140	139
0	Aromatic Chemicals	47	75	172	106	77	45	47
Capex	Specialty Chemicals	69	87	74	91	81	148	216
×	Information &Advanced Materials	32	70	92	47	45	18	18
	Other	0	0	0	0	1	3	1
	Natural Gas Chemicals	45	46	54	64	75	86	77
Эерг	Aromatic Chemicals	36	37	52	77	79	78	77
eci;	Specialty Chemicals	71	80	96	97	86	80	84
Depreciation	Information &Advanced Materials	35	36	42	51	51	42	35
3	Other	0	0	0	0	4	4	3

Appendix 2: Key indicators (2)



3. Performance assumptions

	FY2005 (FY2005 (Results)		FY2006 (Results)		FY2007 (Results)		FY2008 (Results)		FY2009 (Results)	
	H1	H2	H1	H2	H1	H2	H1	H2	HI	H2	
Methanol (US\$/MT)	279	238	276	376	332	398	424	336	195	246	
Raw Xylene (US\$/MT)	690	740	1,000	870	960	950	1,200	600	770	870	
Bisphenol A (US\$/MT)	1,200 ~2,000	1,000 ~1,300	1,200 ~1,600	1,600 ~1,700	1,800 ~2,000	1,800 ~2,000	1,800 ~2,000	800 ~1,500	1,000 ~1,300	1,200 ~1,700	
Polycarbonate (US\$/MT)	3,200 ~3,300	3,000 ~3,300	2,900 ~3,100	2,400 ~2,750	2,600 ~2,850	2,400 ~2,850	2,450 ~2,850	1,900 ~2,450	1,900 ~2,400	2,400 ~2,900	
Exchange rate (JPY/US\$)	110	117	115	119	119	109	106	95	96	90	

	FY2010 (Results)		FY2011 (Results)		FY2012		Downly
	H1	H2	H1	H2	H1 (results)	H2 (forecasts)	Remarks
Methanol (US\$/MT)	283	307	349	385	385	370	Asia spot average price
Raw Xylene (US\$/MT)	830	1,050	1,260	1,280	1,190	1,200	Spot price (FOB-Korea)
Bisphenol A (US\$/MT)	1,800 ~2,100	2,100 ~2,500	2,000 ~2,500	1,400 ~1,800	1,500 ~1,800	1,500 ~1,800	Average CIF price
Polycarbonate (US\$/MT)	2,450 ~2,950	2,400 ~2,900	2,800 ~3,000	2,600 ~2,900	2,500 ~2,800	2,500 ~2,900	
Exchange rate (JPY/US\$)	89	82	80	78	79	80	